Announcement Date Sample Clauses

Announcement Date. The definition of “Announcement Date” in Section 12.1(l) of the Equity Definitions is hereby amended by (i) replacing the words “a firm” with the word “any” in the second and fourth lines thereof, (ii) replacing the word “leads to the” with the words “, if completed, would lead to a” in the third and the fifth lines thereof, (iii) replacing the words “voting shares” with the word “Shares” in the fifth line thereof, and (iv) inserting the words “by any entity” after the word “announcement” in the second and the fourth lines thereof. Nationalization, Insolvency or Delisting: Cancellation and Payment (Calculation Agent Determination); provided that, in addition to the provisions of Section 12.6(a)(iii) of the Equity Definitions, it will also constitute a Delisting if the Exchange is located in the United States and the Shares are not immediately re-listed, re-traded or re-quoted on any of the New York Stock Exchange, The NASDAQ Global Select Market or The NASDAQ Global Market (or their respective successors); if the Shares are immediately re-listed, re-traded or re-quoted on any of the New York Stock Exchange, The NASDAQ Global Select Market or The NASDAQ Global Market (or their respective successors), such exchange or quotation system shall thereafter be deemed to be the Exchange. Additional Disruption Events: Change in Law: Applicable; provided that (i) Section 12.9(a)(ii) of the Equity Definitions is hereby amended by replacing the parenthetical beginning after the word “regulation” in the second line thereof with the words “(including, for the avoidance of doubt and without limitation, (x) any tax law or (y) adoption or promulgation of new regulations authorized or mandated by existing statute),” and (ii) Section 12.9(a)(ii)(X) of the Equity Definitions is hereby amended by replacing the word “Shares” with the phraseHedge Positions.” Failure to Deliver: Not Applicable Insolvency Filing: Applicable Hedging Disruption: Applicable; provided that:
AutoNDA by SimpleDocs
Announcement Date. “Announcement Date” shall mean the date on which the CDFI Fund announces the Recipients of CMF Awards under the applicable NOFA, as indicated on the signature page of this Assistance Agreement.
Announcement Date. This is normally not more than 14 days after the Allocation Date. It is the date on which the WCF MC announces the players who have been awarded Ranking Places and Wild Card Places.
Announcement Date. Section 1.8(a)(ii)........... 4
Announcement Date. The definition of “Announcement Date” in Section 12.1 of the Equity Definitions shall be amended by (i) replacing the word “leads to the” in the third and the fifth lines thereof with the words “, if completed, would lead to a”; (ii) replacing the words “voting shares” in the fifth line thereof with the word “Shares”; (iii) inserting the words “by any entity” after the word “announcement” in the second and the fourth lines thereof; (iv) replacing the words “a firm” with the word “any” in the second and fourth lines thereof; (v) inserting the words “or to explore the possibility of engaging in” after the words “engage in” in the second line thereto; and (vi) inserting the words “or to explore the possibility of purchasing or otherwise obtaining” after the word “obtain” in the fourth line thereto.
Announcement Date. Feb 04 2013 205 : sum of upfront and potential development and commercial Deal value, US$m: milestone payments • Details • Financials • Termsheet • Press ReleaseFiling DataContract Details Announcement date: Feb 04 2013 Start date: Feb 03 2013 Bigbiotech Bigpharma Industry sectors: Biotech Pharmaceutical Compound name: ALN-PCSsc Asset type: Compound Therapy areas: Cardiovascular » Hypercholesterolemia Biological compounds Peptides Technology types: Deal components: Stages of development: Proteomics RNA therapeutics Small molecules Development Licensing Marketing Preclinical Phase I Financials Deal value, US$m: 205 : sum of upfront and potential development and commercial milestone payments Upfront, US$m: 25 : sum of upfront payment Milestones, US$m: 180 : sum of potential development and commercial milestone payments n/d : scaled double-digit royalties on global products sales of ALN-PCS Royalty rates, %: products Termsheet The Medicines Company and Alnylam Pharmaceuticals they have formed an exclusive global alliance for the development and commercialization of Alnylam’s ALN-PCS RNAi therapeutic program for the treatment of hypercholesterolemia. PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that regulates low-density lipoprotein (LDL) receptor levels on hepatocytes; gain-of-function human mutations in PCSK9 are associated with hypercholesterolemia while loss-of-function mutations are associated with lower levels of LDL cholesterol and a reduced risk of cardiovascular disease. ALN-PCS is a PCSK9 synthesis inhibitor that reduces intracellular and extracellular levels of PCSK9 resulting in lowered plasma levels of LDL-C. The Medicines Company and Alnylam intend to collaborate on the advancement of the ALN-PCS program. Alnylam’s ALN-PCS program includes ALN-PCS02 - an intravenously administered RNAi therapeutic which has completed a Phase I trial, and ALN-PCSsc - a subcutaneously administered RNAi therapeutic currently in pre-clinical development. Alnylam will continue the program for an estimated one to two years to complete certain pre-clinical and Phase I clinical studies. The Medicines Company is responsible for leading and funding development from Phase II forward and commercializing the ALN-PCS program if successful. Under the terms of the agreement, The Medicines Company will make an upfront cash payment of $25 million to Alnylam. Alnylam may also receive potential development and commercial milestone payments of up to $180 m...
Announcement Date. The Programme will be announced by a repeated one-round public tender in research, experimental development and innovations (hereinafter referred to as the “Public Tender”). It is expected that between 2010 and 2013 one Public Tender will be announced every year. The first Public Tender will be announced in April 2010.
AutoNDA by SimpleDocs
Announcement Date. Your employment with the Company shall commence on September 8, 2021 (the “Effective Date”). You agree to work with the Company in good faith to announce your acceptance of the Chief Executive Officer position on August 16, 2021. Position: Sole Chief Executive Officer of TPCO Holding Corp. In this full-time, exempt position as the Company’s most senior executive officer, you will render services commensurate with your office, which will include those usual and customary duties and responsibilities and as may be prescribed by the board of directors of the Employer (collectively, the “Board”). You shall report solely to the Board. You may work remotely subject to requisite business travel. Compensation: Annual rate of base salary USD$550,000 (the “Base Salary”) to be paid in accordance with Employer’s regular payroll practices. Your Base Salary will be reviewed at least annually with the opportunity (but not obligation) for merit increases, by the Board or the Compensation Committee of the Board. All cash compensation paid to you shall be in United States dollars. None of the payments or benefits provided (or to be provided) to you shall be subject to offset or mitigation. Terms of Employment: Your employment terms will be subject to the published personnel policies of Employer and its affiliates including, without limitation, rules relating to privacy, non-discrimination, use of Employer’s property, technology use matters, confidentiality, non-competition, solicitation of employees, vendors and customers, conflicts of interest, non-hostile work environment, non-discrimination, and other matters. Bonuses: Within 10 business days of the Effective Date, the Company will deliver to you a one-time signing bonus of $540,000, settled in cash, as consideration for joining the Company (“Signing Bonus”). To the extent your term of employment is shorter than 12-months, other than due to termination by the Company without Cause or by you for Good Reason (as defined below) or due to your death or “Disability” (as defined by USA Internal Revenue Code Section 22(e)(3)), a pro-rated portion of the Signing Bonus will be returned to the Company. For example, if you resign your employment six months after the Effective Date (other than for Good Reason), you would be obligated to return half of the Signing Bonus. Further, you will be entitled to participate in the Company’s annual bonus plan (“Annual Bonus”) applicable to other senior executives, on the terms and subject to th...
Announcement Date. The “Announcement Date” with respect to a share of Series F Preferred Stock shall mean the Trading Day immediately following that Trading Day, during the 20 Trading Day period immediately following the date of receipt of a Conversion Notice with respect to such share of Series F Preferred Stock, on which the Closing Price of a share of Common Stock is closest to, without going over, the arithmetic average of the individual daily volume weighted average prices for the lowest three Trading Days during such 20 Trading Day period.
Announcement Date. Notwithstanding Section 12.1(l) of the Equity Definitions, an “Announcement Date” means, in respect of an Announcement Event, the date on which such Announcement Event occurs. Consequences of Merger Events: Merger Event:
Time is Money Join Law Insider Premium to draft better contracts faster.